Innovative Approach for the Prevention of Chemotherapy-Induced Peripheral Neuropathy in Cancer Patients: A Pilot Study With the Hilotherm Device, the Poliambulanza Hospital Experience.
Hilotherm
chemotherapy-induced peripheral neuropathy
cooling device
neuroprotection
paclitaxel
Journal
Integrative cancer therapies
ISSN: 1552-695X
Titre abrégé: Integr Cancer Ther
Pays: United States
ID NLM: 101128834
Informations de publication
Date de publication:
Historique:
entrez:
29
8
2020
pubmed:
29
8
2020
medline:
19
8
2021
Statut:
ppublish
Résumé
Chemotherapy-induced peripheral neuropathy (CIPN) is an adverse event of taxanes, with no effective prevention or treatment available and a highly negative impact on patient quality of life. The aim of this study is to asses that the constant application of cooled cuffs on the hands and feet prevent and mitigate CIPN. Patients with breast, gynecologic, and pancreatic cancer who received weekly paclitaxel (PTX), PTX/carboplatin, and nab-paclitaxel (nab-PTX)/gemcitabine for any indication at the therapeutic scheduled dosage were included in this prospective study. Hilotherm Chemo care device forms a closed-loop system with cuffs and tubes through which a coolant flows at a temperature of 10 °C. CIPN was monitored using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (edition 3.0), and the tolerability and side effects were scored by using the Common Terminology Criteria for Adverse Events (T4.03 2017). To date, we have enrolled 64 patients. Of these, 54 (84%) completed all cooling cycles. Continuous cooling was well tolerated by all patients. No patients had grade >2 CIPN or had serious or lasting adverse events as a result of Hilotherapy. The median time to CIPN onset was 77 days for the entire population. Hilotherapy has good effectiveness and tolerability and seems to be able to prevent or reduce the symptoms of CIPN. We are still recruiting patients to obtain more data and to collect data at 3 months after the end of chemotherapy. Prospective studies seem to be warranted.
Sections du résumé
BACKGROUND
Chemotherapy-induced peripheral neuropathy (CIPN) is an adverse event of taxanes, with no effective prevention or treatment available and a highly negative impact on patient quality of life. The aim of this study is to asses that the constant application of cooled cuffs on the hands and feet prevent and mitigate CIPN.
METHODS
Patients with breast, gynecologic, and pancreatic cancer who received weekly paclitaxel (PTX), PTX/carboplatin, and nab-paclitaxel (nab-PTX)/gemcitabine for any indication at the therapeutic scheduled dosage were included in this prospective study. Hilotherm Chemo care device forms a closed-loop system with cuffs and tubes through which a coolant flows at a temperature of 10 °C. CIPN was monitored using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (edition 3.0), and the tolerability and side effects were scored by using the Common Terminology Criteria for Adverse Events (T4.03 2017).
RESULTS
To date, we have enrolled 64 patients. Of these, 54 (84%) completed all cooling cycles. Continuous cooling was well tolerated by all patients. No patients had grade >2 CIPN or had serious or lasting adverse events as a result of Hilotherapy. The median time to CIPN onset was 77 days for the entire population.
CONCLUSION
Hilotherapy has good effectiveness and tolerability and seems to be able to prevent or reduce the symptoms of CIPN. We are still recruiting patients to obtain more data and to collect data at 3 months after the end of chemotherapy. Prospective studies seem to be warranted.
Identifiants
pubmed: 32856475
doi: 10.1177/1534735420943287
pmc: PMC7457652
doi:
Substances chimiques
Antineoplastic Agents
0
Paclitaxel
P88XT4IS4D
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1534735420943287Références
Breast. 2019 Dec;48:89-97
pubmed: 31590108
Front Oncol. 2017 Jan 10;6:274
pubmed: 28119855
Korean J Pain. 2013 Jan;26(1):65-71
pubmed: 23342211
N Engl J Med. 2008 Apr 17;358(16):1663-71
pubmed: 18420499
Support Care Cancer. 2020 Mar;28(3):1183-1197
pubmed: 31209630
J Pain Symptom Manage. 2014 Jun;47(6):1100-15
pubmed: 24210702
Support Care Cancer. 2011 Jun;19(6):833-41
pubmed: 20496177
Support Care Cancer. 2014 Aug;22(8):2261-9
pubmed: 24789421
Pain. 2014 Dec;155(12):2461-70
pubmed: 25261162
Curr Neuropharmacol. 2006 Apr;4(2):165-72
pubmed: 18615126
J Natl Cancer Inst. 2020 Jan 1;112(1):55-62
pubmed: 31093677
Support Care Cancer. 2015 Apr;23(4):943-51
pubmed: 25245776
Nurs Res. 2007 Sep-Oct;56(5):323-31
pubmed: 17846553
J Clin Oncol. 2014 Jun 1;32(16):1739-47
pubmed: 24799477
Oncotarget. 2017 Dec 19;9(7):7322-7331
pubmed: 29484113
Breast Cancer Res Treat. 2016 Nov;160(1):61-67
pubmed: 27620884
Brain Behav. 2016 Oct 26;7(1):e00558
pubmed: 28127506
Breast. 2019 Oct;47:22-27
pubmed: 31302389
Support Care Cancer. 2018 Oct;26(10):3461-3469
pubmed: 29681015
Breast Cancer Res Treat. 2013 Nov;142(1):109-18
pubmed: 24132874
Curr Med Chem. 2008;15(29):3081-94
pubmed: 19075655
Pain Pract. 2012 Mar;12(3):219-51
pubmed: 21797961
Chin J Cancer. 2017 Mar 7;36(1):27
pubmed: 28270181
J Pharm Health Care Sci. 2016 Nov 15;2:33
pubmed: 27891244
Cochrane Database Syst Rev. 2007 Oct 17;(4):CD004421
pubmed: 17943815
FASEB J. 2012 Nov;26(11):4696-709
pubmed: 22889832
World J Surg Oncol. 2013 Jan 25;11:19
pubmed: 23351188
J Pain Palliat Care Pharmacother. 2013 Dec;27(4):359-64
pubmed: 24143893
Clin Transl Oncol. 2010 Feb;12(2):81-91
pubmed: 20156778
Gynecol Oncol. 2014 Dec;135(3):510-7
pubmed: 25281491
Curr Med Chem. 2019;26(25):4698-4708
pubmed: 30621553
Crit Rev Oncol Hematol. 2020 Jan;145:102831
pubmed: 31783290
Cancer Epidemiol Biomarkers Prev. 2010 Aug;19(8):1893-907
pubmed: 20647400
Pain Ther. 2018 Jun;7(1):59-75
pubmed: 29594972
Medicine (Baltimore). 2020 Jan;99(3):e18830
pubmed: 32011497
Pain Res Manag. 2019 Jun 12;2019:8346161
pubmed: 31281559
Clin Interv Aging. 2017 Apr 21;12:709-720
pubmed: 28461745
Asia Pac J Clin Oncol. 2018 Oct;14(5):e448-e454
pubmed: 29280313
Gynecol Oncol. 2016 Jan;140(1):176-83
pubmed: 26556766
J Pain Symptom Manage. 2007 Oct;34(4):403-12
pubmed: 17616338
Arthroscopy. 2006 Oct;22(10):1141.e1-6
pubmed: 17027420
J Palliat Med. 2010 Nov;13(11):1389-91
pubmed: 21091028
Crit Rev Oncol Hematol. 2008 Jun;66(3):218-28
pubmed: 18329278
Support Care Cancer. 2020 Aug;28(8):3763-3769
pubmed: 31828491
Int J Mol Sci. 2019 Mar 22;20(6):
pubmed: 30909387
Pain Res Manag. 2017;2017:8053474
pubmed: 28458593
J Clin Oncol. 2008 Apr 1;26(10):1642-9
pubmed: 18375893
Crit Rev Oncol Hematol. 2015 Oct;96(1):34-45
pubmed: 26004917
Pain Physician. 2016 Sep-Oct;19(7):E1049-53
pubmed: 27676676
Cancer Treat Rev. 2010 Feb;36(1):69-74
pubmed: 19945225
Cancer. 2008 Apr 1;112(7):1625-31
pubmed: 18286527
Gynecol Oncol. 2018 Jun;149(3):455-463
pubmed: 29605500
J Oncol Pract. 2014 Nov;10(6):e421-e424
pubmed: 29424607
J Pain Symptom Manage. 2010 Dec;40(6):883-91
pubmed: 20813492
J Hand Ther. 2001 Jul-Sep;14(3):208-15
pubmed: 11511016
Int J Clin Oncol. 2013 Feb;18(1):132-8
pubmed: 22105895
Eur J Cancer. 2018 Sep;101:12-19
pubmed: 30007894
Trials. 2018 Sep 29;19(1):526
pubmed: 30268158
Breast. 2020 Feb;49:219-224
pubmed: 31901783
JAMA. 2013 Apr 3;309(13):1359-67
pubmed: 23549581
J Natl Cancer Inst. 2018 Feb 1;110(2):141-148
pubmed: 29924336
Neurosci Lett. 2015 Jun 2;596:90-107
pubmed: 25459280
J Clin Oncol. 2005 Jul 1;23(19):4424-9
pubmed: 15994152
Ginekol Pol. 2018;89(4):200-4
pubmed: 29781075
Crit Rev Oncol Hematol. 2019 Jul;139:16-23
pubmed: 31112878
Support Care Cancer. 2016 Jun;24(6):2807-14
pubmed: 27041741